Central Nervous System Drugs Market by Drug Classes, Diseases, Drug Type, Distribution Channel

Description

List of Tables

The Global Central Nervous System Drugs Market is forecasted to grow significantly, with a projected USD 20.71 billion in 2023 at a CAGR of 9.60% and expected to reach a staggering USD 39.99 billion by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Central Nervous System Drugs Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Central Nervous System Drugs Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Drug Classes, market is studied across Analgesics, Anesthetics, Anti-Epileptics, Anti-Parkinson Drugs, and Antidepressant. The Analgesics commanded largest market share of 22.49% in 2022, followed by Antidepressant.

Based on Diseases, market is studied across CNS Trauma, Infectious Diseases, Mental Health, Neurodegenerative Diseases, and Neurovascular Diseases. The Infectious Diseases commanded largest market share of 28.56% in 2022, followed by Mental Health.

Based on Drug Type, market is studied across Biologics and Non-Biologics. The Non-Biologics commanded largest market share of 71.68% in 2022, followed by Biologics.

Based on Distribution Channel, market is studied across Hospital Pharmacies, Online, and Retail Pharmacies. The Retail Pharmacies commanded largest market share of 62.58% in 2022, followed by Hospital Pharmacies.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Europe, Middle East & Africa commanded largest market share of 41.45% in 2022, followed by Americas.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Central Nervous System Drugs Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Central Nervous System Drugs Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Central Nervous System Drugs Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Central Nervous System Drugs Market?

4. What is the competitive strategic window for opportunities in the Global Central Nervous System Drugs Market?

5. What are the technology trends and regulatory frameworks in the Global Central Nervous System Drugs Market?

6. What is the market share of the leading vendors in the Global Central Nervous System Drugs Market?

7. What modes and strategic moves are considered suitable for entering the Global Central Nervous System Drugs Market?

Product Code: MRR-434CCDA051A0

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Central Nervous System Drugs Market, by Drug Classes, 2022 vs 2030
4.3. Central Nervous System Drugs Market, by Diseases, 2022 vs 2030
4.4. Central Nervous System Drugs Market, by Drug Type, 2022 vs 2030
4.5. Central Nervous System Drugs Market, by Distribution Channel, 2022 vs 2030
4.6. Central Nervous System Drugs Market, by Region, 2022 vs 2030

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Growing incidence of neurological and cognitive disorders across the globe
  - 5.1.1.2. Ascending government programs and awareness activities to spread the knowledge about neurological risk factors and symptoms
  - 5.1.1.3. Rise in geriatric population with neurological complications
- 5.1.2. Restraints
  - 5.1.2.1. Requirement of high capital investment and adequate infrastructure for drug discovery and development
- 5.1.3. Opportunities
  - 5.1.3.1. Ongoing drug evolvement to meet the unique and changing demands of psychiatry and neurology field
  - 5.1.3.2. Adoption of artificial intelligence and machine learning in CNS drug discovery
- 5.1.4. Challenges
  - 5.1.4.1. Stringent regulations for product approvals and concern regarding product recalls
  - 5.1.4.2. Dearth of subject expertise in the neurological field amid the competent studies
5.2. Market Trends
5.3. Cumulative Impact of COVID-19
5.4. Cumulative Impact of Russia-Ukraine Conflict
5.5. Cumulative Impact of High Inflation
5.6. Porter's Five Forces Analysis
- 5.6.1. Threat of New Entrants
- 5.6.2. Threat of Substitutes
- 5.6.3. Bargaining Power of Customers
- 5.6.4. Bargaining Power of Suppliers
- 5.6.5. Industry Rivalry
5.7. Value Chain & Critical Path Analysis
5.8. Regulatory Framework
5.9. Client Customization

6. Central Nervous System Drugs Market, by Drug Classes

6.1. Introduction
6.2. Analgesics
6.3. Anesthetics
6.4. Anti-Epileptics
6.5. Anti-Parkinson Drugs
6.6. Antidepressant

7. Central Nervous System Drugs Market, by Diseases

7.1. Introduction
7.2. CNS Trauma
7.3. Infectious Diseases
7.4. Mental Health
7.5. Neurodegenerative Diseases
7.6. Neurovascular Diseases

8. Central Nervous System Drugs Market, by Drug Type

8.1. Introduction
8.2. Biologics
8.3. Non-Biologics

9. Central Nervous System Drugs Market, by Distribution Channel

9.1. Introduction
9.2. Hospital Pharmacies
9.3. Online
9.4. Retail Pharmacies

10. Americas Central Nervous System Drugs Market

10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States

11. Asia-Pacific Central Nervous System Drugs Market

11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam

12. Europe, Middle East & Africa Central Nervous System Drugs Market

12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom

13. Competitive Landscape

13.1. FPNV Positioning Matrix
13.2. Market Share Analysis, By Key Player
13.3. Competitive Scenario Analysis, By Key Player
- 13.3.1. Merger & Acquisition
  - 13.3.1.1. Neuraxpharm announces closing of acquisition of established products from Sanofi
  - 13.3.1.2. Intrinsic Medicine enters merger deal with Phoenix Biotech
  - 13.3.1.3. Solid Biosciences Announces Acquisition of AavantiBio and Concurrent $75 Million Private Placement
  - 13.3.1.4. AbbVie Acquires Syndesi Therapeutics, Strengthening Neuroscience Portfolio
- 13.3.2. Agreement, Collaboration, & Partnership
  - 13.3.2.1. Astex and Cardiff University announce drug discovery collaboration
  - 13.3.2.2. PrecisionLife and Ono sign multi-target partnership for CNS disorders
  - 13.3.2.3. Collaboration will focus on therapy targets for CNS disorders
  - 13.3.2.4. Gensaic enters into collaboration to develop
  - 13.3.2.5. IAMA Therapeutics Partners with the Italian Institute of Technology to Embark on Landmark Research on Neuroscience Drug Discovery
  - 13.3.2.6. AbbVie and Gedeon Richter Announce Collaboration in Neuropsychiatric Diseases

14. List of Company Mentioned

15. Appendix

15.1. Discussion Guide
15.2. License & Pricing